Cetuximab targeted therapy explained

It is selected according to the cancer site, tumour biology, treatment history and the person's health. Being targeted does not mean it affects only cancer cells or has no side effects.

EGFR is a receptor on the outside of certain cells. Cetuximab binds to it and disrupts signals involved in cell growth and survival. The presence of EGFR alone may not be enough to predict benefit. Depending on the cancer, molecular changes elsewhere in the signalling pathway can influence whether the medicine is suitable. Pathology and molecular reports must therefore be matched to the exact diagnosis. Cetuximab may be used alone or combined with another cancer treatment according to the agreed plan.

Before the first infusion, tell the oncology unit about allergies, heart or lung problems, all medicines and any prior infusion reaction. Attend requested blood tests because treatment can disturb minerals in the blood and may require replacement. Skin effects often resemble acne but need cancer-team guidance rather than ordinary acne products. Report rash, itching, dry cracks, nail inflammation, diarrhoea, mouth soreness or red eyes while symptoms are still manageable. Gentle moisturiser, sun protection and prescribed treatments may be included in your care plan.

An infusion reaction can begin with breathing difficulty, wheeze, throat or facial swelling, chest tightness, faintness, chills or sudden flushing. Notify staff immediately if any appear. Seek emergency care after leaving the unit if breathing becomes difficult, you collapse, or swelling develops quickly. Call the oncology team without delay for fever, spreading skin redness, pus, extensive blistering, severe diarrhoea, marked weakness, palpitations, confusion, very low urine output or inability to keep fluids down.

Ask which pathology or molecular finding supports cetuximab, whether it will be combined with another treatment, and what outcome the team will monitor. Confirm the planned schedule, blood-test checks, skin-care prescription and emergency contact route. It is also useful to know what side effect would prompt a pause or dose change and what other option would be considered if the cancer does not respond.